CiNTech: Technological Hub for Innovation, Translation, and Industrialization of Complex Injectable Medicines
Plan | Recovery and Resilience Plan (Plano de Recuperação e Resiliência – PRR)
Structuring Dimension | RE. Resilience
Support under | C05. Business Capitalization and Innovation
Investment Name | RE-C05-i01.01 – Mobilizing Agendas/Alliances for Business Innovation
Consortium Leader | BLUEPHARMA – PHARMACEUTICAL INDUSTRY S.A.
Agenda Description |
CiNTech aims to create and empower the 1st Technological Hub for Innovation, Translation, and Industrialization dedicated to complex injectable medicines: innovative technological platforms capable of incorporating different therapeutic agents for oncology (small molecules, peptides, nucleic acids). It will be a unique Hub comprising 3 Centers: an I&I (Innovation and Industrialization) laboratory for knowledge and technology translation; development, process engineering, and scale-up to enable analytical development and prototyping; GMP manufacturing capable of producing injectables, whether developed by the consortium or third parties.
This will be a structuring and mobilizing project with a high impact on the economy and scientific innovation in Portugal, promoting synergistic cooperation between SMEs, non-SMEs, and R&D institutions and creating a highly differentiated portfolio that, in addition to the benefits for patients, contributes to the export of high-tech goods and services.
Start Date | 01.01.2023
End Date | 31.12.2025
Total Investment | 29 466 225,37 €
MRR (Recovery and Resilience Mechanism) / Next Generation EU Incentive | 21 777 108,29 €
Beneficiary Entity | Biotrend S.A.
Beneficiary Investment | 1 508 238,91€
Beneficiary Incentive | 950 679,18 €
Objectives, Activities, and Expected Results |
Development, optimization, and scale-up of microbial fermentation processes for the production of nucleic acids for incorporation into complex injectable medicines. Acquisition of specific skills in nucleic acid production, based on existing knowledge for the production of other macromolecules, such as recombinant proteins, for highly regulated industries. Capacity-building of the company through the adoption and optimization of state-of-the-art macromolecule purification techniques. Production of product batches for application testing and the design of a production protocol suitable for transfer to GMP production conditions. Adoption of Industry 4.0 tools for laboratory and process management. Qualification of the team with new technological, regulatory, and quality-related knowledge. Implementation of a quality management process and its certification.